Dehbanipour Razieh, Maleki Vala Taghi Zadeh, Ghalavand Zohreh
PhD, Department of Microbiology, School of Medicine, Yasuj University of Medical Sciences, Yasuj, Iran.
Biology student, Faculty of Arts and Science, Department of Biology, Concordia University, Montreal, Canada.
Germs. 2025 Jun 30;15(2):166-188. doi: 10.18683/germs.2025.1466. eCollection 2025 Jun.
The heteroresistance phenotype refers to the presence of bacterial subpopulations with reduced antibiotic susceptibility compared with the main population. Mathematical modelling and computer simulations suggest that heteroresistance can lead to negative treatment outcomes and finally, treatment failure. Due to the low frequency and resistance level of resistant subpopulations, detection of heteroresistance phenotype in the diagnostic laboratory is problematic. Routine laboratory tests do not have the ability to accurately detect heteroresistance, but on the other hand, specific methods are time consuming and expensive. The emergence of colistin heteroresistance is a public health concern that threatens human health. Colistin heteroresistance to date has been reported in eight pathogens including spp., spp., spp., spp., serovar Typhimurium (referred to as ), and The growing emergence of colistin heteroresistance worldwide underscores the crucial need for coordinated global action to combat it. Understanding the mechanisms of colistin heteroresistance can help to provide better guidelines for reducing antibiotic resistance and to achieve new therapeutic approaches. Our review showed that the prevalence of colistin heteroresistance strains varies in different countries. It seems that the use of different treatment strategies, especially combination therapy, can be effective in reducing the incidence of resistant subpopulations. Also, the use of new generation diagnostic methods can have a significant impact on treatment. Our findings in this review are needed to raise the awareness of microbiologists and specialists to the colistin heteroresistance mechanisms and to achieve effective treatment.
异质性耐药表型是指与主要菌群体相比,存在抗生素敏感性降低的细菌亚群。数学建模和计算机模拟表明,异质性耐药可导致负面的治疗结果,最终导致治疗失败。由于耐药亚群的频率低且耐药水平低,在诊断实验室检测异质性耐药表型存在问题。常规实验室检测无法准确检测异质性耐药,但另一方面,特定方法既耗时又昂贵。黏菌素异质性耐药的出现是一个威胁人类健康的公共卫生问题。迄今为止,已在8种病原体中报道了黏菌素异质性耐药,包括 菌属、 菌属、 菌属、 菌属、鼠伤寒血清型(称为 )、 菌属和 菌属。全球范围内黏菌素异质性耐药的不断出现凸显了采取协调一致的全球行动来对抗它的迫切需要。了解黏菌素异质性耐药的机制有助于为降低抗生素耐药性提供更好的指导方针,并实现新的治疗方法。我们的综述表明,黏菌素异质性耐药菌株的流行率在不同国家有所不同。似乎使用不同的治疗策略,尤其是联合治疗,可能有效地降低耐药亚群的发生率。此外,使用新一代诊断方法可能对治疗产生重大影响。我们在本综述中的发现需要提高微生物学家和专家对黏菌素异质性耐药机制的认识,并实现有效的治疗。